BioNxt Solutions Inc.
BNXT
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -89.29% | -92.82% | -41.07% | 19.27% | -12.69% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -89.29% | -92.82% | -41.07% | 19.27% | -12.69% |
| Cost of Revenue | -- | -- | -- | -- | -76.41% |
| Gross Profit | -83.03% | 113.43% | 163.87% | 189.32% | 251.00% |
| SG&A Expenses | -26.02% | -35.07% | 2.52% | 0.18% | -39.18% |
| Depreciation & Amortization | -45.18% | -26.85% | -19.51% | -12.74% | -48.14% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.06% | -30.29% | -5.21% | -5.43% | -35.57% |
| Operating Income | 15.79% | 26.44% | 3.29% | 6.57% | 36.60% |
| Income Before Tax | 50.83% | 53.12% | 38.57% | 41.00% | 9.83% |
| Income Tax Expenses | -- | -- | -- | -- | -313.99% |
| Earnings from Continuing Operations | 48.92% | 51.37% | 36.10% | 38.70% | 12.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.92% | 51.37% | 36.10% | 38.70% | 12.50% |
| EBIT | 15.79% | 26.44% | 3.29% | 6.57% | 36.60% |
| EBITDA | 15.30% | 26.79% | 3.31% | 6.86% | 36.76% |
| EPS Basic | 55.92% | 57.83% | 44.86% | 46.95% | 28.24% |
| Normalized Basic EPS | 25.93% | 32.75% | 17.36% | 22.82% | 48.31% |
| EPS Diluted | 55.92% | 57.83% | 44.86% | 46.95% | 28.24% |
| Normalized Diluted EPS | 25.93% | 32.75% | 17.36% | 22.82% | 48.31% |
| Average Basic Shares Outstanding | 14.45% | 15.74% | 18.56% | 19.59% | 21.25% |
| Average Diluted Shares Outstanding | 14.45% | 15.74% | 18.56% | 19.59% | 21.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
